<p>Natixis 在第二季度购买了 Nuvation Bio Inc.（纽约证券交易所代码：NUVB - 免费报告）的新头寸，根据其最近向证券交易委员会（SEC）提交的 13F 表格。该公司购买了 905,500 股该公司的股票，价值约为 1,766,000 美元。截至其最近向证券交易委员会（SEC）提交的文件，Natixis 持有 Nuvation Bio 约 0.27% 的股份。</p>
<p>其他对冲基金和机构投资者最近也对该公司的头寸进行了调整。Pale Fire Capital SE 在第二季度将其在 Nuvation Bio 的股份提高了 109.5%。Pale Fire Capital SE 现在拥有 95,642 股该公司的股票，价值 187,000 美元，此前在该期间内购买了额外的 50,000 股。Cerity Partners LLC 在第二季度购买了 Nuvation Bio 的新头寸，价值约为 97,000 美元。Morton Community Bank 在第二季度购买了 Nuvation Bio 的股票，价值 59,000 美元。Cresset Asset Management LLC 在第二季度将其在 Nuvation Bio 的股份增加了 3.5%。Cresset Asset Management LLC 现在拥有 143,690 股该公司的股票，价值 280,000 美元，此前在该期间内获得了额外的 4,874 股。最后，Tema Etfs LLC 在第二季度购买了 Nuvation Bio 的新股份，价值 272,000 美元。对冲基金和其他机构投资者持有该公司 61.67% 的股份。</p>
<h2>内部买卖</h2>
<p>在 Nuvation Bio 的其他新闻中，内部人士 Dongfang Liu 在 12 月 1 日星期一出售了 150,000 股该公司的股票。该股票以平均价格 7.82 美元出售，总交易额为 1,173,000.00 美元。交易完成后，内部人士在公司中持有 18,000 股，价值 140,760 美元。这笔交易代表了其头寸的 89.29% 的减少。该交易已在向 SEC 的文件中披露，相关信息可通过此链接获取。此外，内部人士 Gary Hattersley 在 10 月 27 日星期一出售了 100,000 股该股票。该股票以平均价格 5.02 美元出售，总价值为 502,000.00 美元。有关此次出售的更多详细信息可在官方 SEC 披露中找到。在过去三个月中，内部人士已出售 320,000 股公司股票，价值 2,050,800 美元。29.93% 的股票由公司内部人士持有。</p>
<h2>华尔街分析师观点</h2>
<p>几位分析师对 NUVB 股票发布了报告。HC Wainwright 在周四的报告中将 Nuvation Bio 的目标价从 10.00 美元上调至 18.00 美元，并给予该公司 “买入” 评级。JMP Securities 在 11 月 20 日的研究报告中对 Nuvation Bio 的股票设定了 10.00 美元的目标价。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Nuvation Bio 的 “卖出（d-）” 评级。Citizens Jmp 在 11 月 20 日的报告中将 Nuvation Bio 的目标价从 8.00 美元上调至 10.00 美元，并给予该公司 “市场表现优于大盘” 评级。最后，Wall Street Zen 在 8 月 17 日的研究报告中将 Nuvation Bio 的评级从 “卖出” 上调至 “持有”。一位分析师给予该股票 “强烈买入” 评级，九位给予 “买入” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 10.56 美元。</p>
<p><strong>阅读我们关于 Nuvation Bio 的最新报告</strong></p>
<h2>Nuvation Bio 股票表现</h2>
<p>周五，NYSE NUVB 的股票开盘价为 8.27 美元。该公司的市值为 28.4 亿美元，市盈率为-12.92，贝塔值为 1.58。Nuvation Bio Inc.的 52 周低点为 1.54 美元，52 周高点为 8.95 美元。该公司的债务与股本比率为 0.14，速动比率为 8.39，流动比率为 8.48。该公司的 50 日移动平均线为 5.59 美元，200 日移动平均线为 3.62 美元。</p>
<p>Nuvation Bio（NYSE:NUVB - 获取免费报告）最近在 11 月 3 日星期一发布了季度收益数据。该公司报告季度每股收益（EPS）为-0.16 美元，超出市场共识预期的-0.17 美元 0.01 美元。Nuvation Bio 的净利润率为-813.07%，股本回报率为-54.99%。该公司在该季度的收入为 1,312 万美元，而市场共识预期为 748 万美元。作为一个整体，分析师预计 Nuvation Bio Inc.在当前财政年度将发布-0.36 美元的每股收益。</p>
<h2>Nuvation Bio 简介</h2>
<p>（免费报告）</p>
<p>Nuvation Bio Inc.是一家临床阶段的生物制药公司，专注于肿瘤学治疗候选药物的开发。该公司的主要产品候选药物是 NUV-868，一种 BD2 选择性口服小分子 BET 抑制剂，能够表观遗传学调节控制肿瘤生长和分化的蛋白质，包括 c-myc 等癌基因；NUV-1156，一种 AR 结合剂 Xtandi，针对晚期前列腺癌，具有进入通常通过外科前列腺切除术治疗的早期阶段的潜力；以及药物 - 药物结合平台（DDC），该平台利用抗癌疗法药物结合类中的新型治疗方法，将抗癌药物输送到癌细胞，同时还有 NUV-1176，一种 PARP 抑制剂，用于治疗 ER+ 乳腺癌和卵巢癌。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，而不是 Nuvation Bio</li>
<li>医疗保健股票解析：为什么你可能想要投资</li>
<li>2026 年要避免的三只最近被下调的股票</li>
<li>股票中的死亡交叉是什么？</li>
<li>芯片热潮回归：三只有巨大收益潜力的股票</li>
<li>现在购买的三只最佳金融科技股票</li>
<li>甲骨文股票遭重创：为什么其 AI 管道可能推动 2026 年反弹</li>
</ul>
<p><strong>想看看其他对冲基金持有的 NUVB 吗？</strong> 访问 HoldingsChannel.com 获取 Nuvation Bio Inc.（NYSE:NUVB - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5VVkI?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5VVkI"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Nuvation Bio 吗？</h2>
<p>在考虑 Nuvation Bio 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Nuvation Bio 并不在名单上。</p>
<p>虽然 Nuvation Bio 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

NUVB

<p>Natixis 在第二季度收购了 905,500 股 Nuvation Bio Inc.，价值 1,766,000 美元。内部人士 Dongfang Liu 出售了 150,000 股，而 Gary Hattersley 出售了 100,000 股。分析师的评级不一，HC Wainwright 将目标价上调至 18.00 美元，而 Weiss Ratings 则发布了卖出评级。Nuvation Bio 的股票开盘价为 8.27 美元，市值为 28.4 亿美元</p>

<p>Natixis bought a new position in Nuvation Bio Inc. (NYSE:NUVB - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 905,500 shares of the company's stock, valued at approximately $1,766,000. Natixis owned about 0.27% of Nuvation Bio as of its most recent filing with the Securities and Exchange Commission (SEC).</p>
<div class="lb-trans"><p>Natixis 在第二季度购买了 Nuvation Bio Inc.（纽约证券交易所代码：NUVB - 免费报告）的新头寸，根据其最近向证券交易委员会（SEC）提交的 13F 表格。该公司购买了 905,500 股该公司的股票，价值约为 1,766,000 美元。截至其最近向证券交易委员会（SEC）提交的文件，Natixis 持有 Nuvation Bio 约 0.27% 的股份。</p>
</div><p>Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Pale Fire Capital SE lifted its stake in shares of Nuvation Bio by 109.5% in the 2nd quarter. Pale Fire Capital SE now owns 95,642 shares of the company's stock worth $187,000 after purchasing an additional 50,000 shares during the period. Cerity Partners LLC bought a new position in Nuvation Bio in the second quarter worth approximately $97,000. Morton Community Bank purchased a new position in shares of Nuvation Bio during the 2nd quarter worth $59,000. Cresset Asset Management LLC grew its position in shares of Nuvation Bio by 3.5% during the 2nd quarter. Cresset Asset Management LLC now owns 143,690 shares of the company's stock valued at $280,000 after acquiring an additional 4,874 shares during the period. Finally, Tema Etfs LLC purchased a new stake in shares of Nuvation Bio in the 2nd quarter worth $272,000. Hedge funds and other institutional investors own 61.67% of the company's stock.</p>
<div class="lb-trans"><p>其他对冲基金和机构投资者最近也对该公司的头寸进行了调整。Pale Fire Capital SE 在第二季度将其在 Nuvation Bio 的股份提高了 109.5%。Pale Fire Capital SE 现在拥有 95,642 股该公司的股票，价值 187,000 美元，此前在该期间内购买了额外的 50,000 股。Cerity Partners LLC 在第二季度购买了 Nuvation Bio 的新头寸，价值约为 97,000 美元。Morton Community Bank 在第二季度购买了 Nuvation Bio 的股票，价值 59,000 美元。Cresset Asset Management LLC 在第二季度将其在 Nuvation Bio 的股份增加了 3.5%。Cresset Asset Management LLC 现在拥有 143,690 股该公司的股票，价值 280,000 美元，此前在该期间内获得了额外的 4,874 股。最后，Tema Etfs LLC 在第二季度购买了 Nuvation Bio 的新股份，价值 272,000 美元。对冲基金和其他机构投资者持有该公司 61.67% 的股份。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In other Nuvation Bio news, insider Dongfang Liu sold 150,000 shares of the firm's stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $7.82, for a total transaction of $1,173,000.00. Following the completion of the transaction, the insider owned 18,000 shares in the company, valued at $140,760. This trade represents a 89.29% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Gary Hattersley sold 100,000 shares of the stock in a transaction that occurred on Monday, October 27th. The shares were sold at an average price of $5.02, for a total value of $502,000.00. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 320,000 shares of company stock valued at $2,050,800. 29.93% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在 Nuvation Bio 的其他新闻中，内部人士 Dongfang Liu 在 12 月 1 日星期一出售了 150,000 股该公司的股票。该股票以平均价格 7.82 美元出售，总交易额为 1,173,000.00 美元。交易完成后，内部人士在公司中持有 18,000 股，价值 140,760 美元。这笔交易代表了其头寸的 89.29% 的减少。该交易已在向 SEC 的文件中披露，相关信息可通过此链接获取。此外，内部人士 Gary Hattersley 在 10 月 27 日星期一出售了 100,000 股该股票。该股票以平均价格 5.02 美元出售，总价值为 502,000.00 美元。有关此次出售的更多详细信息可在官方 SEC 披露中找到。在过去三个月中，内部人士已出售 320,000 股公司股票，价值 2,050,800 美元。29.93% 的股票由公司内部人士持有。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Several analysts have issued reports on NUVB shares. HC Wainwright boosted their price target on Nuvation Bio from $10.00 to $18.00 and gave the company a &#34;buy&#34; rating in a report on Thursday. JMP Securities set a $10.00 target price on shares of Nuvation Bio in a research note on Thursday, November 20th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Nuvation Bio in a research note on Wednesday, October 8th. Citizens Jmp raised their price target on Nuvation Bio from $8.00 to $10.00 and gave the company a &#34;market outperform&#34; rating in a report on Thursday, November 20th. Finally, Wall Street Zen upgraded Nuvation Bio from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Sunday, August 17th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $10.56.</p>
<div class="lb-trans"><p>几位分析师对 NUVB 股票发布了报告。HC Wainwright 在周四的报告中将 Nuvation Bio 的目标价从 10.00 美元上调至 18.00 美元，并给予该公司 “买入” 评级。JMP Securities 在 11 月 20 日的研究报告中对 Nuvation Bio 的股票设定了 10.00 美元的目标价。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Nuvation Bio 的 “卖出（d-）” 评级。Citizens Jmp 在 11 月 20 日的报告中将 Nuvation Bio 的目标价从 8.00 美元上调至 10.00 美元，并给予该公司 “市场表现优于大盘” 评级。最后，Wall Street Zen 在 8 月 17 日的研究报告中将 Nuvation Bio 的评级从 “卖出” 上调至 “持有”。一位分析师给予该股票 “强烈买入” 评级，九位给予 “买入” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 10.56 美元。</p>
</div><p><strong>Read Our Latest Report on Nuvation Bio</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Nuvation Bio 的最新报告</strong></p>
</div><h2>Nuvation Bio Stock Performance</h2>
<div class="lb-trans"><h2>Nuvation Bio 股票表现</h2>
</div><p>Shares of NYSE NUVB opened at $8.27 on Friday. The company has a market cap of $2.84 billion, a P/E ratio of -12.92 and a beta of 1.58. Nuvation Bio Inc. has a 52-week low of $1.54 and a 52-week high of $8.95. The company has a debt-to-equity ratio of 0.14, a quick ratio of 8.39 and a current ratio of 8.48. The firm's fifty day moving average is $5.59 and its two-hundred day moving average is $3.62.</p>
<div class="lb-trans"><p>周五，NYSE NUVB 的股票开盘价为 8.27 美元。该公司的市值为 28.4 亿美元，市盈率为-12.92，贝塔值为 1.58。Nuvation Bio Inc.的 52 周低点为 1.54 美元，52 周高点为 8.95 美元。该公司的债务与股本比率为 0.14，速动比率为 8.39，流动比率为 8.48。该公司的 50 日移动平均线为 5.59 美元，200 日移动平均线为 3.62 美元。</p>
</div><p>Nuvation Bio (NYSE:NUVB - Get Free Report) last released its quarterly earnings data on Monday, November 3rd. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.01. Nuvation Bio had a negative net margin of 813.07% and a negative return on equity of 54.99%. The business had revenue of $13.12 million during the quarter, compared to the consensus estimate of $7.48 million. As a group, analysts anticipate that Nuvation Bio Inc. will post -0.36 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Nuvation Bio（NYSE:NUVB - 获取免费报告）最近在 11 月 3 日星期一发布了季度收益数据。该公司报告季度每股收益（EPS）为-0.16 美元，超出市场共识预期的-0.17 美元 0.01 美元。Nuvation Bio 的净利润率为-813.07%，股本回报率为-54.99%。该公司在该季度的收入为 1,312 万美元，而市场共识预期为 748 万美元。作为一个整体，分析师预计 Nuvation Bio Inc.在当前财政年度将发布-0.36 美元的每股收益。</p>
</div><h2>Nuvation Bio Profile</h2>
<div class="lb-trans"><h2>Nuvation Bio 简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.</p>
<div class="lb-trans"><p>Nuvation Bio Inc.是一家临床阶段的生物制药公司，专注于肿瘤学治疗候选药物的开发。该公司的主要产品候选药物是 NUV-868，一种 BD2 选择性口服小分子 BET 抑制剂，能够表观遗传学调节控制肿瘤生长和分化的蛋白质，包括 c-myc 等癌基因；NUV-1156，一种 AR 结合剂 Xtandi，针对晚期前列腺癌，具有进入通常通过外科前列腺切除术治疗的早期阶段的潜力；以及药物 - 药物结合平台（DDC），该平台利用抗癌疗法药物结合类中的新型治疗方法，将抗癌药物输送到癌细胞，同时还有 NUV-1176，一种 PARP 抑制剂，用于治疗 ER+ 乳腺癌和卵巢癌。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Nuvation Bio</li>
<li>Health Care Stocks Explained: Why You Might Want to Invest</li>
<li>3 Recently Downgraded Stocks to Avoid in 2026</li>
<li>What is a Death Cross in Stocks?</li>
<li>The Chip Boom Is Back: 3 Stocks Positioned for Huge Gains</li>
<li>The 3 Best Fintech Stocks to Buy Now</li>
<li>Oracle Stock Hit Hard: Why Its AI Pipeline Could Drive a 2026 Rally</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，而不是 Nuvation Bio</li>
<li>医疗保健股票解析：为什么你可能想要投资</li>
<li>2026 年要避免的三只最近被下调的股票</li>
<li>股票中的死亡交叉是什么？</li>
<li>芯片热潮回归：三只有巨大收益潜力的股票</li>
<li>现在购买的三只最佳金融科技股票</li>
<li>甲骨文股票遭重创：为什么其 AI 管道可能推动 2026 年反弹</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding NUVB?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nuvation Bio Inc. (NYSE:NUVB - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 NUVB 吗？</strong> 访问 HoldingsChannel.com 获取 Nuvation Bio Inc.（NYSE:NUVB - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5VVkI" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=NUVB"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Nuvation Bio Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Nuvation Bio 吗？</h2>
</div><p>Before you consider Nuvation Bio, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Nuvation Bio 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nuvation Bio wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Nuvation Bio 并不在名单上。</p>
</div><p>While Nuvation Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Nuvation Bio 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Natixis 购买了 905,500 股 Nuvation Bio Inc.的股票，股票代码为 NUVB